Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 16/20 | 0.58 |
| ▸ | OPRM1 | P35372 | 11/20 | 0.58 |
| ▸ | OPRD1 | P41143 | 11/20 | 0.58 |
| ▸ | OPRK1 | P41145 | 11/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3591423 | 0.80 | CCR3 (0.57) | OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL7815717 | 0.79 | OPRL1 (0.68) | OPRL1OPRM1OPRD1OPRK1POLB | |
| SCHEMBL10060840 | 0.79 | OPRL1 (0.68) | OPRL1OPRM1OPRD1OPRK1POLB | |
| SCHEMBL11213153 | 0.79 | OPRL1 (0.58) | OPRL1OPRM1OPRD1OPRK1POLB | |
| SCHEMBL21077926 | 0.79 | OPRL1 (0.58) | OPRL1OPRM1OPRD1OPRK1POLB | |
| SCHEMBL21652005 | 0.79 | OPRL1 (0.58) | OPRL1OPRM1OPRD1OPRK1POLB | |
| SCHEMBL153569 | 0.79 | OPRL1 (0.59) | OPRL1OPRM1OPRD1OPRK1POLB | |
| SCHEMBL13754263 | 0.79 | OPRL1 (0.58) | OPRL1OPRM1OPRD1OPRK1POLB | |
| SCHEMBL11473746 | 0.79 | OPRL1 (0.67) | OPRL1OPRM1OPRD1OPRK1POLB | |
| SCHEMBL27345562 | 0.78 | OPRL1 (0.56) | OPRL1OPRM1OPRD1OPRK1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130210769-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2013-08-15 | — | — | US | claimed |
| US-20100234365-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2010-09-16 | — | — | US | claimed |
| EP-2121598-A2 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2009-11-25 | — | — | EP | claimed |
| WO-2008076754-A2 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2008-06-26 | — | — | WO | claimed |
| US-20130210769-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2013-08-15 | — | — | US | disclosed |
| US-8431607-B2 | Compounds and compositions as inhibitors of cannabinoid receptor 1 activity | IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) | 2013-04-30 | — | — | US | disclosed |
| US-20100234365-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2010-09-16 | — | — | US | disclosed |
| EP-2121598-A2 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2009-11-25 | — | — | EP | disclosed |
| US-7541478-B2 | Coumarin derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-02 | — | — | US | disclosed |
| WO-2008076754-A2 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2008-06-26 | — | — | WO | disclosed |
| US-20070197636-A1 | Coumarin Derivative And Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-08-23 | — | — | US | disclosed |
| US-20070179154-A1 | Coumarin derivatives, process for their production and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-08-02 | — | — | US | disclosed |
| US-6974806-B2 | Lipid-rich plaque inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-12-13 | — | — | US | disclosed |
| WO-2005082879-A1 | COUMARIN DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-09-09 | — | — | WO | disclosed |
| CN-1615305-A | Coumarin derivatives, process for their production and use thereof | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2005-05-11 | — | — | CN | disclosed |
| US-20050020634-A1 | Coumarin derivatives, process for their production and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-01-27 | — | — | US | disclosed |
| EP-1471064-A1 | COUMARIN DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-10-27 | — | — | EP | disclosed |
| US-20030232809-A1 | Lipid-rich plaque inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-12-18 | — | — | US | disclosed |
| CN-1441794-A | Lipid-rich plaque degrading agent | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-09-10 | — | — | CN | disclosed |
| EP-1302470-A1 | LIPID-RICH PLAQUE INHIBITORS | Takeda Chemical Industries, Ltd. (JP) | 2003-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020634-A1 | Coumarin derivatives, process for their production and use thereof | CBR1, ACAT2, CBR3 | OPRL1 4267/4885OPRM1 3128/4885OPRD1 3256/4885 |
| US-20070197636-A1 | Coumarin Derivative And Use Thereof | CBR3, HCCS, CBR1 | OPRL1 2908/4885OPRM1 1107/4885OPRD1 917/4885 |
| US-20030232809-A1 | Lipid-rich plaque inhibitors | LDLR, NR1H2, NR1H3 | OPRL1 2318/4885OPRM1 3364/4885OPRD1 2168/4885 |
| US-20070179154-A1 | Coumarin derivatives, process for their production and use thereof | CBR1, CBR3, ACAT2 | OPRL1 4293/4885OPRM1 3063/4885OPRD1 3379/4885 |
| US-20130210769-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | CNR1, CNR2, FAAH | OPRL1 8/4885OPRM1 18/4885OPRD1 30/4885 |
| US-20100234365-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | CNR1, CNR2, FAAH | OPRL1 8/4885OPRM1 18/4885OPRD1 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.